Study Reveals Potential New Therapy for Interstitial Lung Disease in Patients with Immunodeficiency
Milwaukee, August 3, 2020 – Research published recently in the Journal of Allergy and Clinical Immunology highlights the successful treatment of an interstitial lung disease in children with common variable immunodeficiency (CVID) pioneered by researchers at the Medical College of Wisconsin (MCW) led by John Routes, MD, professor of pediatrics, medicine, microbiology and immunology at MCW and chief of allergy and clinical immunology at Children’s Wisconsin. As Children’s is a national referral center for CVID patients, and in particular those with interstitial lung disease, the work of these local researchers has the potential to change the standard practice on how this disease is treated.
CVID is an antibody deficiency that leaves the immune system unable to defend itself against bacteria and viruses, resulting in severe ear, sinus and respiratory infections. CVID can occur at any time in life, but in the U.S., the most common age of onset is in the second decade of life. Patients who have been diagnosed with CVID are also at risk of contracting a life threatening complication, granulomatous and lymphocytic interstitial lung disease (GLILD). GLILD occurs in approximately 20-30 percent of CVID patients and is one of the most common causes of death, yet there has not been an established standard of care for the treatment of this disorder. In the past steroids were used, but they have been proven ineffective.
Dr. Routes is hopeful that this study will change the standard practice on how the disease is treated. “There is a widespread lack of understanding of CVID and GLILD,” he said. “Our results suggest that combination immunosuppression should be considered as first-line therapy in the treatment of GLILD.”
Because it is now known that a CVID-like immunodeficiency can result from mutations in genes involved in immunity, the researchers also conducted whole exome sequencing on all the patients. As a result, they found mutations in more than 20 percent of the patients, but the immunosuppressive treatment was equally effective in patients with or without a damaging mutation.
Recent Press Releases by Medical College of Wisconsin
Advancing a Healthier Wisconsin Endowment Announces Availability of up to $6 Million in Funding to Improve Health, Advance Health Equity StatewideSep 1st, 2020 by Medical College of Wisconsin
Application period now open for four funding opportunities available to community organizations and medical researchers in Wisconsin